Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3001517 | 0.89 | PTGDR2 (0.68) | PTGDR2AKR1B1 | |
| SCHEMBL1788367 | 0.88 | PTGDR2 (1.00) | PTGDR2AKR1B1 | |
| SCHEMBL1386840 | 0.81 | PTGDR2 (0.81) | PTGDR2AKR1B1 | |
| Ammonia Solution, Strong SCHEMBL4395485 | 0.81 | PTGDR2 (0.79) | PTGDR2AKR1B1 | |
| SCHEMBL1385122 | 0.80 | PTGDR2 (0.87) | PTGDR2AKR1B1 | |
| SCHEMBL13588621 | 0.78 | PTGDR2 (0.80) | PTGDR2AKR1B1 | |
| SCHEMBL1386979 | 0.78 | PTGDR2 (1.00) | PTGDR2AKR1B1 | |
| SCHEMBL3559891 | 0.78 | PTGDR2 (0.53) | PTGDR2AKR1B1 | |
| SCHEMBL1386058 | 0.77 | PTGDR2 (0.73) | PTGDR2AKR1B1 | |
| SCHEMBL1384838 | 0.77 | PTGDR2 (0.77) | PTGDR2AKR1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4791729-B2 | — | — | 2011-10-12 | — | — | JP | claimed |
| JP-2005537265-A | — | — | 2005-12-08 | — | — | JP | claimed |
| EP-1551802-A1 | INDOLE-3-SULPHUR DERIVATIVES | AstraZeneca AB (SE) | 2005-07-13 | — | — | EP | claimed |
| WO-2004007451-A1 | INDOLE-3-SULPHUR DERIVATIVES | ASTRAZENECA AB (SE) | 2004-01-22 | — | — | WO | claimed |
| US-20140328861-A1 | Combination of CRTH2 Antagonist and a Proton Pump Inhibitor for the Treatment of Eosinophilic Esophagitis | ATOPIX THERAPEUTICS LTD (GB) | 2014-11-06 | — | — | US | disclosed |
| EP-2790696-A1 | COMBINATION OF CRTH2 ANTAGONIST AND A PROTON PUMP INHIBITOR FOR THE TREATMENT OF EOSINOPHILIC ESOPHAGITIS | Atopix Therapeutics Limited (GB) | 2014-10-22 | — | — | EP | disclosed |
| WO-2013088109-A1 | COMBINATION OF CRTH2 ANTAGONIST AND A PROTON PUMP INHIBITOR FOR THE TREATMENT OF EOSINOPHILIC ESOPHAGITIS | OXAGEN LIMITED (GB) | 2013-06-20 | — | — | WO | disclosed |
| EP-1551802-A1 | INDOLE-3-SULPHUR DERIVATIVES | AstraZeneca AB (SE) | 2005-07-13 | — | — | EP | disclosed |
| WO-2004007451-A1 | INDOLE-3-SULPHUR DERIVATIVES | ASTRAZENECA AB (SE) | 2004-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140328861-A1 | Combination of CRTH2 Antagonist and a Proton Pump Inhibitor for the Treatment of Eosinophilic Esophagitis | HRH2, HRH1, HRH4 | PTGDR2 59/4885AKR1B1 3801/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.